Variables | No. of patients (%) | OS since CNS metastases, mo (95% CI) | P value |
---|---|---|---|
Age (yrs) | Â | Â | 0.150 |
  <60 | 16 (55.2) | 15.3 (3.7-26.9) |  |
  > = 60 | 13 (44.8) | 9.4 (4.9-13.9) |  |
FIGO stage | Â | Â | 0.069 |
  1,2 | 3 (10.3) | 32.3 (16.9-47.7) |  |
  3,4 | 26 (89.7) | 11.7 (9.5-13.9) |  |
Pathology of primary cancer | Â | 0.824 | |
  Serous | 16 (55.2) | 11.7 (9.9-13.5) |  |
  Non-serous | 13 (44.8) | 15.3 (6.1-24.5) |  |
Histological grade | Â | Â | 0.391 |
  1,2 | 5 (21.7) | 22.7 (3.7-41.7) |  |
  3, | 18 (78.3) | 11.7 (9.6-13.8) |  |
Extent of surgical resection | Â | 0.211* | |
  TAH + BSO | 23 (79.3) | 13.2 (7.6-18.8) |  |
  Limited | 5 (17.2) | 16.2 (4.5-19.3) |  |
  Biopsy | 1 (3.4) | 1.0 |  |
Lymph node metastasis | Â | 0.372 | |
  No | 11 (37.9) | 20.4 (8.4-32.4) |  |
  Yes | 18 (62.1) | 11.7 (9.4-14.0) |  |
Ascites at the time of primary surgery | 0.421 | ||
  No | 10 (34.5) | 15.3 (1.7-28.9) |  |
  Yes | 19 (65.5) | 12.5 (9.9-15.1) |  |
Adjuvant therapy |  |  | 0.071†|
  Chemotherapy | 25 (86.2) | 15.3 (8.0-22.6) |  |
  Chemotherapy + Radiotherapy | 3 (10.3) | 7.0 (1.5-12.4) |  |
  None | 1 (3.4) | 32.3 |  |
Platinum sensitivity | Â | Â | 0.033 |
  Sensitive | 16 (57.1) | 15.3 (0.5-30.1) |  |
  Resistant | 12 (42.9) | 9.4 (0.1-18.9) |  |
CD133 expression in primary cancer | Â | 0.001 | |
  Negative | 15 (51.7) | 25.5 (10.4-40.6) |  |
  VPositive | 14 (48.3) | 9.4 (2.4-16.4) |  |
KPS score | Â | Â | 0.412 |
  > = 80 | 14 (48.3) | 13.2 (1.0-29.2) |  |
  <80 | 15 (51.7) | 12.5 (1.1-23.9) |  |
No. of metastases | Â | Â | 0.027 |
  Single | 11 (37.9) | 25.5 (12.6-38.4) |  |
  Multiple | 18 (62.1) | 9.4 (4.4-14.4) |  |
Prior cancer relapse before the diagnosis of CNS metastasis | 0.053 | ||
  No | 24 (82.8) | 15.3 (6.4-24.2) |  |
  Yes | 5 (17.2) | 9.4 (3.3-21.2) |  |
Presence of extracranial disease | Â | 0.458 | |
  No | 16 (55.2) | 13.2 (3.1-23.3) |  |
  Yes | 13 (44.8) | 12.5 (5.4-19.6) |  |
Treatment of CNS metastases |  | 0.027‡ | |
  Steroids | 2 (6.9) | 1.0 (0–5.292) |  |
  Unimodal (WBRT or Neurosurgery) | 9 (31.0) | 8.0 (3.0-13.0) |  |
  Multimodal including WBRT (Neurosurgery + WBRT +/− chemotherapy) | 10 (34.5) | 13.2 (7.5-18.9) |  |
  Multimodal including SRS (SRS +/− neurosurgery +/− chemotherapy) | 8 (27.6) | 27.3 (15.1-39.5) |  |
CD133 expression in CNS metastases |  | 0.005§ | |
  Negative | 3 (15.8) | 42.1 (31.4-46.2) |  |
  Positive single cell | 4 (21.1) | 27.3 (25.1-29.6) |  |
  Positive cluster | 12 (63.2) | 11.6 (8.5-14.7) |  |
Time to CNS metastases (mo) | Â | 0.122 | |
  <23.5 | 14 (48.3) | 7.6 (0.78-20.25) |  |
  > = 23.5 | 15 (51.7) | 15.3 (1.41-29.19) |  |